pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,357 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1852Endpoints1437Fierce Biotech752BioSpace741BioPharma Dive544raps246onclive165fda recalls
therapy area
allOncology12810Rare Disease3305Immunology2978Cardiology2841Hematology2280Pulmonology2226Vaccines
  • Roche opens new research center in Boston, expanding its local presence
    Roche announced the opening of a new research facility in Boston, adding to its existing operations in the city. The center will focus on early-stage drug discovery and will house several hundred…
    STAT · 2mo agoPositive↗ source
  • Electra Therapeutics raises $350 million in Nasdaq IPO to fund commercial expansion
    Electra Therapeutics announced that it priced its initial public offering on the Nasdaq at $350 million, becoming the 21st biotech to go public in 2026. The Bay Area‑based company said the capital…
    Endpoints · 2mo agoDealPositive↗ source
← prev
page 56 of 175
next →
118
fda medwatch113
globenewswire health73
fda press61
1838
Psychiatry & CNS1229
Ophthalmology1127
Endocrinology & Metabolism794
Pain788
Nephrology779
  • Electra Therapeutics raises $350M in biotech IPO, fueling rare disease drug development
    Electra Therapeutics completed a $350 million initial public offering, becoming the 21st biotechnology company to go public in 2026. The strong demand for its shares highlights continued investor a…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • All 50 states, DC, and Puerto Rico join new Medicaid most-favored-nation drug pricing model, Trump says
    President Donald Trump announced that every U.S. state, the District of Columbia and Puerto Rico will take part in a new Medicaid drug‑pricing framework. The model requires pharmaceutical manufact…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • Trump announces GENEROUS model, securing pharma deals to cut Medicaid drug prices
    President Trump announced a new initiative called the GENEROUS model that is intended to lower drug prices for state Medicaid programs. The program will involve all 50 states, Washington, D.C., an…
    STAT · 2mo agoDealNeutral↗ source
  • FDA reports decline in initial drug rejections, refutes claims of rising denials
    The U.S. Food and Drug Administration announced that the number of drugs turned down after an initial review has fallen, contrary to recent speculation. The agency said the notion that it is incre…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • China unveils new five-year plan to boost biotech and pharma and compete globally
    China's government released its latest five-year plan aimed at expanding the country's biotech and pharmaceutical sectors. The document outlines a strategy to strengthen research, development and m…
    Endpoints · 2mo agoRegulatoryPositive↗ source
  • GSK adds two China cancer-therapy licensing deals, keeping pace with industry partnership surge
    BioPharma Dive's new visualization series recapped recent activity, spotlighting GSK's licensing agreements in China and the market response. Since the start of 2025, GSK has signed five deals wit…
    BioPharma Dive · 2mo agoDealNeutral↗ source
  • Ultragenyx prices Sanfilippo gene therapy at $4 million as it gains a second FDA approval; Bristol Myers halts Orum cancer drug
    The FDA approved Fayuvi, the first gene therapy for Sanfilippo syndrome Type A, with a list price of $3.95 million. This marks Ultragenyx's second gene‑therapy approval since August, earning sella…
    BioPharma Dive · 2mo agoApprovalNeutral↗ source
  • U.S. drafts new investment rules to keep pharma licensing deals with China viable
    The United States is drafting new guidelines that would govern how American investors can fund Chinese biotech and pharmaceutical companies. The proposed framework is intended to address national‑s…
    STAT · 2mo agoRegulatoryPositive↗ source
  • Sudan civil war forces cancer patients to endure hazardous journeys for treatment
    Medical missionary Tom Catena has run the Mother of Mercy hospital in the Nuba Mountains for over a decade, but the ongoing civil war has crippled Sudan’s health system. The remote facility, the la…
    STAT · 2mo agoNegative↗ source
  • Spectra Medical recalls Sodium Chloride Flush ampules due to serious safety risk
    Spectra Medical Devices has issued a recall of its Sodium Chloride Injection 0.9% USP 10 mL flush ampules that were manufactured by Huons Co., Ltd. The FDA classified the recall as the most serious…
    fda medwatch · 2mo agoCRLNegative↗ source
  • Legend Biotech appoints former Novartis exec Ingrid Zhang as CEO amid falling share price
    Legend Biotech announced the appointment of Ingrid Zhang, a former Novartis executive, as its new chief executive officer. The leadership change comes as the company faces growing competition for…
    Endpoints · 2mo agoNeutral↗ source
  • HCA Healthcare sues Independence Blue Cross over $345,000 in unpaid Texas hospital claims
    Several Texas hospitals owned by HCA Healthcare have filed a lawsuit against Independence Blue Cross, a Philadelphia‑based insurer, seeking more than $345,000 in unpaid medical claims dating back r…
    STAT · 2mo agoRegulatoryNegative↗ source
  • FDA faces nominee hearing, hiring woes and reviews of psychedelics and testosterone therapies
    A Senate committee set a hearing for President Trump's pick to lead the FDA, highlighting the political scrutiny of the agency's top leadership. New reporting reveals ongoing hiring challenges at…
    raps · 2mo agoRegulatoryNeutral↗ source
  • Anthropic opens limited access to Mythos AI for life-science researchers
    Anthropic announced it is beginning a verification program that will let a select group of life-science researchers use its Mythos large-language model. When Mythos was first released on July 1, t…
    Endpoints · 2mo agoPositive↗ source
  • Doctors urged to tell patients Asian glow signals health risk, not harmless quirk
    Brian Zhang, a second-year medical student at Stanford and student body president, wrote an opinion piece urging doctors to discuss the so-called "Asian glow" with patients. The facial flushing th…
    STAT · 2mo agoNeutral↗ source
  • FDA updates instructions for NOxBOXi nitric oxide delivery system after leak risk identified
    The FDA has issued a correction for the NOxBOXi nitric oxide delivery system with the NOxMixer module after discovering that the device can leak oxygen during inhaled nitric oxide therapy. The age…
    fda medwatch · 2mo agoCRLNeutral↗ source
  • China biotech policy debate moves to Washington for live discussion
    Endpoints News brought its ongoing China biotech debate to the nation’s capital, arranging a live session with officials shaping upcoming regulations. The event featured interviews with several po…
    Endpoints · 2mo agoNeutral↗ source
  • Panel discusses how questions about health equity shape public trust in science
    Anil Oza reported that he participated in a National Academies of Science roundtable focused on population health and how research communication influences public trust. The discussion highlighted…
    STAT · 2mo agoNeutral↗ source
  • IN8bio appoints Oxana Polyakova as senior vice president of R&D
    IN8bio announced a new senior vice president for research and development. Oxana Polyakova joins the company after serving as chief scientific officer at LAVA Therapeutics. Her background in drug…
    STAT · 2mo agoPositive↗ source
  • Geriatrician urges careful use of AI predictions for older patients
    Artificial intelligence tools are being added to electronic health records to flag patients at risk for conditions such as sepsis, falls or even death. The ease of integration has led many clinicia…
    STAT · 2mo agoNeutral↗ source
  • Rise in Young Men Seeking Cosmetic Surgery Driven by Social Media Influence, Surgeon Observes
    A board‑certified plastic surgeon in Boston reports that more young men are now filling her waiting room than ever before, making men the fastest‑growing group in aesthetic procedures. Procedures…
    STAT · 2mo agoNeutral↗ source
  • Roche's Lunsumio clears Phase 3 hurdle, paving way for broader label in indolent lymphoma
    Roche announced that its T cell engager Lunsumio successfully met the primary endpoints in a Phase 3 study of a slow growing blood cancer. The trial, conducted in patients with indolent lymphoma,…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • North Immunology to go public via reverse merger with Aethlon, targeting eczema market
    North Immunology, an early-stage biotech developing a dual-acting antibody for eczema, announced plans to become a public company through a reverse merger with Aethlon Medical. The transaction wil…
    BioPharma Dive · 2mo agoDealPositive↗ source